Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rapamycin for amyotrophic lateral sclerosis
2016-002399-28Phase 2Completed
- Sponsor
- AOU Policlinico di Modena
- Start
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in amyotrophic lateral sclerosis (ALS) comparing Sirolimus with Placebo (2 arms). Primary endpoint: Positive regulatory T-cell response at week 18. Started Jan 2018; status: completed.
02
Drugs
sirolimus
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on 2016-002399-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002399-28.